Triple Therapy in Type 2 Diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients (original) (raw)

OBJECTIVE -To evaluate the efficacy and safety of add-on insulin glargine versus rosiglitazone in insulin-naïve patients with type 2 diabetes inadequately controlled on dual oral therapy with sulfonylurea plus metformin. randomized, parallel trial, 217 patients (HbA 1c [A1C] 7.5-11%, BMI Ͼ25 kg/m 2 ) on Ն50% of maximal-dose sulfonylurea and metformin received add-on insulin glargine 10 units/day or rosiglitazone 4 mg/day. Insulin glargine was forced-titrated to target fasting plasma glucose (FPG) Յ5.5-6.7 mmol/l (Յ100 -120 mg/dl), and rosiglitazone was increased to 8 mg/day any time after 6 weeks if FPG was Ͼ5.5 mmol/l.

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact